


FIG. 1A




FIG. 1C




FIG. 1B



Relative mRNA expression normalized to Gapdh
Cdkn1a (p21)
Mdm2
Puma
Bax
Gadd45a
Molm13
Oci/AML3
μM
NT
0.1
0.2
0.4
0.5
1
1.5
5
10

FIG. 2



Molm14 (p53 WT)
ML2 (p53 WT)
[Aileron peptide 1]
NT
1 μM
2.5 μM
5 μM
10 μM
NT
1 μM
2.5 μM
5 μM
10 μM
Mdm2
p53
p21
Actin

FIG. 3A



Molm13
OCI/AML3
HL60
NT
24hr
48hr
72hr
NT
24hr
48hr
72hr
NT
24hr
48hr
72hr
1μM Aileron peptide 1
Mdm2
p53
p21
β-Actin

FIG. 3B




FIG. 4B




FIG. 4A




FIG. 4C




FIG. 5A




FIG. 5B

FIG. 5C




FIG. 5D



number of colonies
600
500
400
300
200
100
0
Molm13
Vehicle
1uM AP1
Oci/AML3
Vehicle
1uM AP1
Molm14
Vehicle
1uM AP1
ML2
Vehicle
1uM AP1
HL60
Vehicle
1uM AP1
p53 Wild Type
p53 Null

FIG. 6





FIG. 7A



*Note: Kasumi-1 cells express a hotspot p53 mutant (R248Q).

FIG. 7B





FIG. 8A






FIG. 8B




FIG. 8C




Aileron peptide 1
vehicle
1.0 uM
5.0 uM
10 uM
DAPI
Annexin- V

FIG. 8D


Moim14
Vehicle
1.0 uM
5.0 uM
10 uM
% of cells
Viable
Early Apoptosis
Late Apoptosis
Necrosis




Aileron peptide 1
vehicle
1.0 uM
5.0 uM
10 uM
DAPI
Annexin- V

FIG. 8E


ML2
% of cells
Viable
Early Apoptosis
Late Apoptosis
Necrosis




FIG. 9A




FIG. 9B




FIG. 9C




FIG. 10B




FIG. 10D




FIG. 10A




FIG. 10C




FIG. 11A




FIG. 11B



AML013
Vehicle
1.0 uM
5.0 uM
10 uM
% of cells
90
80
70
60
50
40
30
20
10
0
Viable
Early Apoptosis
Late Apoptosis
Necrosis
vehicle
1.0 uM
5.0 uM
10 uM
DAPI
Annexin- V

FIG. 12




FIG. 13




FIG. 14



1250
1000
750
500
250
0
Mean tumor volume ± SEM (mm3)
Vehicle 3x/week
SP154 30 mg/kg 3x/week
SP154 40 mg/kg 2x/week
16
23
30
37
Days post-tumor cell implant

FIG. 15



1250
1000
750
500
250
0
Mean tumor volume ± SEM (mm3)
Vehicle 3x/week
SP249 6.67 mg/Kg 3x/week
16
23
30
37
Days post-tumor cell implant

FIG. 16



1250
1000
750
500
250
0
Mean tumor volume ± SEM (mm³)
Vehicle 3x/week
SP315 26.7 mg/Kg 3x/week
SP315 20 mg/Kg 2x/week
SP315 30 mg/Kg 2x/week
SP315 40 mg/Kg 2x/week
16
23
30
37
Days post-tumor cell implant

FIG. 17



1250
1000
750
500
250
0
Vehicle 3x/week
SP252 30 mg/Kg 3x/week
Mean tumor volume ± SEM (mm³)
16
23
30
37
Days post-tumor cell implant

FIG. 18



Solubility (mg/mL)
# of amino acids C-terminal to cross-link
SP316
SP315
SP69
Peptide 193
SP# | Solubility (mg/mL)
Peptide 193 (Table 2b) | <=1
SP69 | 3
SP315 | 4.5
SP316 | 5

FIG. 19




Peptidomimetic Macrocyce, µM
2.5
5
10
% Annexin-V+
100
90
80
70
60
50
40
30
20
10
0
PLX4032 (10 µM)
Peptidomimetic Macrocycle
PLX (10 µM) + Peptidomimetic Macrocycle

FIG. 20



PM = Peptidomimetic macrocycle

FIG. 21



HCT116
p53 -/-
DMSO
10uM
HCT116
p53 +/+
DMSO
10uM
SP-252
HCT116
p53 -/-
DMSO
10uM
HCT116
p53 +/+
DMSO
10uM
SP-154
p53
PDL1
actin

FIG. 22



WST-1
measure time
270 min
210 min
150 min
120 min
90 min
60 min
30 min
OD450
0
1
2
3
4
0
20000
40000
60000
80000
100000
MCF-7 Cell number

FIG. 23




FIG. 24A




FIG. 24B




FIG. 25A




FIG. 25B



MCF-7 Cell Proliferation (WST-1/OD 450 nm)
0.0
0.5
1.0
1.5
0
0.03
0.1
0.3
1
3
10
30
100
300
900
Fulvestrant (nM)

FIG. 26




FIG. 27A




FIG. 27B




FIG. 28B




FIG. 28A



MCF-7 Cell Proliferation (WST-1/OD 450 nm)
0.0
0.5
1.0
1.5
Everolimus (μM)
0
0.0001
0.0003
0.001
0.003
0.01
0.03
0.1
0.3
1
3

FIG. 29




FIG. 30A




FIG. 30B




FIG. 31B




FIG. 31A



MOLT-3Cell Proliferation (WST-1/OD 450 nm)
0.0
0.5
1.0
Romidepsin (nM)
0
0.1
0.2
0.25
0.5
1
1.5
2
2.5
3
10
30

FIG. 32




FIG. 33A




FIG. 33B




FIG. 34A




FIG. 34B




FIG. 34C



MCF-7 Cell Proliferation (WST-1/OD 450 nm)
1.5
1.0
0.5
0.0
0
0.001
0.003
0.01
0.03
0.1
0.3
1
3
10
30
Palbociclib (μM)

FIG. 35




FIG. 36A




FIG. 36B




FIG. 37B




FIG. 37A




FIG. 38A




FIG. 38B



Ara-C
Log(CI)
2
1
0
-1
-2
0
0.5
1
Fa
Effect Range
antagonism
additivity
synergy

FIG. 38C




FIG. 39A




FIG. 39B



Azacitidine
antagonism
additivity
synergy
Log(CI)
2
1
0
-1
-2
0
0.5
1
Fa
Effect Range

FIG. 39C




FIG. 40A




FIG. 40B



Decitabine
antagonism
additivity
synergy
Log(CI)
2
1
0
-1
-2
0
0.5
1
Fa
Effect Range

FIG. 40C




FIG. 41A




FIG. 41B



Midosaturin
2
1
0
-1
-2
Log(CI)
0
0.5
1
Fa
antagonism
additivity
synergy
Effect Range

FIG. 41C




FIG. 42A




FIG. 42B



Vincristine
antagonism
additivity
synergy
Log(CI)
2
1
0
-1
-2
0
0.5
1
Fa
Effect Range

FIG. 42C



DOHH-2 Cell Proliferation (Fraction of control Cells)
1.2
0.8
0.4
0.0
Control
0.1 μM AP1
1 nM VCR
0.1 μM AP1 + 1 nM VCR
0.3 μM AP1
1 nM VCR
0.3 μM AP1 + 1 nM VCR

FIG. 43




FIG. 44A




FIG. 44B




FIG. 44C

	IC_{50} (mM)
CTX	1.981
CTX + 0.07 μM AP1	0.4109
CTX + 0.2 μM AP1	0.1718
CTX + 0.6 μM AP1	0.2579



DOHH-2 Cell Proliferation (Fraction of control Cells)
1.2
0.8
0.4
0.0
Control
0.3 μM AP1
1.0 mM CTX
0.3 μM AP1 + 1.0 mM CTX

FIG. 45



AP1 + VCR, Simultaneously
AP1 pretreat 24 hrs
VCR pretreat 24 hrs
Fraction of Control Cells
1.5
1.0
0.5
0.0
Control
0.025 µM AP1 + 0.125 nM VCR
0.05 µM AP1 + 0.25 nM VCR
0.1 µM AP1 + 0.5 nM VCR
0.2 µM AP1 + 1.0 nM VCR
0.4 µM AP1 + 2.0 nM VCR
0.8 µM AP1 + 4.0 nM VCR
1.6 µM AP1 + 8.0 nM VCR

FIG. 46



AP1 pretreat 24 hrs
AP1
AP1 + 0.3 nM VCR
AP1 + 1.0 nM VCR
AP1 + 3.0 nM VCR
VCR pretreat 24 hrs
AP1
AP1 + 0.3 nM VCR
AP1 + 1.0 nM VCR
AP1 + 3.0 nM VCR
DOHH-2 Cell Proliferation (Fraction of control Cells)
1.5
1.0
0.5
0.0
-4
-2
0
2
AP1 (log,μM)

FIG. 47



AP1 pretreat 24 hrs
VCR
VCR + 0.07 mMAP1
VCR + 0.2 mM AP1
VCR + 0.6 mM AP1
VCR pretreat 24 hrs
VCR
VCR + 0.07 mMAP1
VCR + 0.2 mM AP1
VCR + 0.6 mM AP1
DOHH-2 Cell Proliferation (Fraction of control Cells)
1.5
1.0
0.5
0.0
-4
-2
0
2
Vincristine (Log, µM)

FIG. 48



AP1 + CTX, Simultaneously
AP1 pretreat 24 hrs
CTX pretreat 24 hrs
Fraction of Control Cells
1.5
1.0
0.5
0.0
Control
0.05 µM AP1 + 0.1 mM CTX
0.1 µM AP1 + 0.2 mM CTX
0.2 µM AP1 + 0.4 mM CTX
0.4 µM AP1 + 0.8 mM CTX
0.8 µM AP1 + 1.6 mM CTX
1.6 µM AP1 + 3.2 mM CTX

FIG. 49



AP1 pretreat 24 hrs
AP1
AP1 + 0.1 mM CTX
AP1 + 0.3 mM CTX
AP1 + 1.0 mM CTX
CTX pretreat 24 hrs
AP1
AP1 + 0.1 mM CTX
AP1 + 0.3 mM CTX
AP1 + 1.0 mM CTX
DOHH-2 Cell Proliferation (Fraction of control Cells)
1.5
1.0
0.5
0.0
-4
-2
0
2
AP1 (log,μM)

FIG. 50



AP1 pretreat 24 hrs
CTX
CTX + 0.07 mMAP1
CTX + 0.2 mM AP1
CTX + 0.6 mM AP1
CTX pretreat 24 hrs
CTX
CTX + 0.07 mMAP1
CTX + 0.2 mM AP1
CTX + 0.6 mM AP1
DOHH-2 Cell Proliferation (Fraction of control Cells)
1.5
1.0
0.5
0.0
-4
-2
0
2
CTX (Log, mM)

FIG. 51



AP1 + Midostaurin, Simultaneously
AP1 pretreat 24 hrs
Midostaurin pretreat 24 hrs
Fraction of Control Cells
1.5
1.0
0.5
0.0
Control
0.0154 µM AP1 + 0.00125 µM Midostaurin
0.0308 µM AP1 + 0.0025 µM Midostaurin
0.0625 µM AP1 + 0.005 µM Midostaurin
0.125 µM AP1 + 0.01 µM Midostaurin
0.25 µM AP1 + 0.02 µM Midostaurin
0.5 µM AP1 + 0.04 µM Midostaurin
1.0 µM AP1 + 0.08 µM Midostaurin

FIG. 52



AP1 pretreat 24 hrs
AP1
AP1 + 3 nM Midostaurin
AP1 + 10 nM Midostaurin
AP1 + 30 nM Midostaurin
Midostaurin pretreat 24 hrs
AP1
AP1 + 3 nM Midostaurin
AP1 + 10 nM Midostaurin
AP1 + 30 nM Midostaurin
MV4-11 Cell Proliferation (Fraction of control cells)
1.5
1.0
0.5
0.0
-4
-2
0
2
AP1 (log,μM)

FIG. 53



AP1 pretreat 24 hrs
Midostaurin
Midostaurin + 0.03 mM AP1
Midostaurin + 0.1 mM AP1
Midostaurin + 0.3 mM AP1
Midostaurin pretreat 24 hrs
Midostaurin
Midostaurin + 0.03 mM AP1
Midostaurin + 0.1 mM AP1
Midostaurin + 0.3 mM AP1
MV4-11 Cell Proliferation (Fraction of control cells)
1.5
1.0
0.5
0.0
-4
-2
0
2
Midostaurin(Log, µM)

FIG. 54



AP1 + Decitabine, Simultaneously
AP1 pretreat 24 hrs
Decitabine pretreat 24 hrs
MV4-11 Cells Proliferation (Fraction of Control Cells)
1.5
1.0
0.5
0.0
Control
0.015625 µM AP1 + 0.0078125 µM Decitabine
0.03125 µM AP1 + 0.015625 µM Decitabine
0.0625 µM AP1 + 0.03125 µM Decitabine
0.125 µM AP1 + 0.0625 µM Decitabine
0.25 µM AP1 + 0.125 µM Decitabine
0.5 µM AP1 + 0.25 µM Decitabine
1 µM AP1 + 0.5 µM Decitabine

FIG. 55



AP1 pretreat 24 hrs
AP1
AP1 + 0.2 μM Decitabine
AP1 + 0.6 μM Decitabine
AP1 + 1.8 μM Decitabine
Decitabine pretreat 24 hrs
AP1
AP1 + 0.2 μM Decitabine
AP1 + 0.6 μM Decitabine
AP1 + 1.8 μM Decitabine
MV4-11 Cell Proliferation (Fraction of control cells)
1.5
1.0
0.5
0.0
-4
-2
0
2
AP1 (log,μM)

FIG. 56



AP1 pretreat 24 hrs
Decitabine
Decitabine + 0.03 μM AP1
Decitabine + 0.1 μM AP1
Decitabine + 0.3 μM AP1
Decitabine pretreat 24 hrs
Decitabine
Decitabine + 0.03 μM AP1
Decitabine + 0.1 μM AP1
Decitabine + 0.3 μM AP1
MV4-11 Cell Proliferation (Fraction of control cells)
1.5
1.0
0.5
0.0
-4
-2
0
2
Decitabine(Log, μM)

FIG. 57



AP1 + ARA-C, Simultaneously
AP1 pretreat 24 hrs
ARA-C pretreat 24 hrs
Fraction of Control Cells
1.5
1.0
0.5
0.0
Control
0.0154 µM AP1 + 0.0154 µM Ara-C
0.0308 µM AP1 + 0.0308 µM Ara-C
0.0625 µM AP1 + 0.0625 µM Ara-C
0.125 µM AP1 + 0.125 µM Ara-C
0.25 µM AP1 + 0.25 µM Ara-C
0.5 µM AP1 + 0.5 µM Ara-C
1.0 µM AP1 + 1.0 µM Ara-C

FIG. 58



AP1 pretreat 24 hrs
AP1
AP1 + 0.05 µM ARA-C
AP1 + 0.15 µM ARA-C
AP1 + 0.45 µM ARA-C
ARA-C pretreat 24 hrs
AP1
AP1 + 0.05 µM ARA-C
AP1 + 0.15 µM ARA-C
AP1 + 0.45 µM ARA-C
MV4-11 Cell Proliferation (Fraction of control cells)
1.5
1.0
0.5
0.0
-4
-2
0
2
AP1 (log,µM)

FIG. 59



AP1 pretreat 24 hrs
ARA-C
ARA-C + 0.03 μM AP1
ARA-C + 0.1 μM AP1
ARA-C + 0.3 μM AP1
ARA-C pretreat 24 hrs
ARA-C
ARA-C + 0.03 μM AP1
ARA-C + 0.1 μM AP1
ARA-C + 0.3 μM AP1
MV4-11 Cell Proliferation (Fraction of control cells)
1.5
1.0
0.5
0.0
-4
-2
0
2
ARA-C (Log, μM)

FIG. 60



AP1 + Azacitidine, Simultaneously
AP1 pretreat 24 hrs
Azacitidine pretreat 24 hrs
Fraction of Control Cells
1.5
1.0
0.5
0.0
Control
0.0154 µM AP1 + 0.125 µM Azacitidine
0.0306 µM AP1 + 0.25 µM Azacitidine
0.0625 µM AP1 + 0.5 µM Azacitidine
0.125 µM AP1 + 1 µM Azacitidine
0.025 µM AP1 + 2 µM Azacitidine
0.5 µM AP1 + 4 µM Azacitidine
1.0 µM AP1 + 8 µM Azacitidine

FIG. 61



AP1 pretreat 24 hrs
AP1
AP1 + 0.3 μM Azacitidine
AP1 + 1.0 μM Azacitidine
AP1 + 3.0 μM Azacitidine
Azacitidine pretreat 24 hrs
AP1
AP1 + 0.3 μM Azacitidine
AP1 + 1.0 μM Azacitidine
AP1 + 3.0 μM Azacitidine
MV4-11 Cell Proliferation (Fraction of control cells)
1.2
0.8
0.4
0.0
-4
-2
0
2
AP1 (log,μM)

FIG. 62



AP1 pretreat 24 hrs
Azacitidine
Azacitidine + 0.03 μM AP1
Azacitidine + 0.1 μM AP1
Azacitidine + 0.3 μM AP1
Azacitidine pretreat 24 hrs
Azacitidine
Azacitidine + 0.03 μM AP1
Azacitidine + 0.1 μM AP1
Azacitidine + 0.3 μM AP1
MV4-11 Cell Proliferation (Fraction of control cells)
1.5
1.0
0.5
0.0
-4
-2
0
2
Azacitidine (Log, μM)

FIG. 63




FIG. 64A




FIG. 64B




FIG. 65A




FIG. 65B




FIG. 66A




FIG. 66B




FIG. 67A




FIG. 67B




FIG. 68A




FIG. 68B




FIG. 69A




FIG. 69B



OD450 nm
1.5
1.0
0.5
0.0
Control
0.1 µM AP1
3 µg/ml Rituximab
0.1 µM AP1 + 3 µg/ml Rituximab
0.3 µM AP1
3 µg/ml Rituximab
0.3 µM AP1 + 3 µg/ml Rituximab

FIG. 70




FIG. 71A




FIG. 71B




FIG. 72A




FIG. 72B

	IC_{50} (μM)
AP1	0.088
AP1+ 0.5 nM Romidepsin	0.1014
AP1+ 1.5 nM Romidepsin	0.038
AP1+ 3 nM Romidepsin	0.028

FIG. 72C



1.0
0.5
0.0
OD450 nm
Control
0.1 µM AP1
1.5 nM Romidepsin
0.1 µM AP1 + 1.5 nM Romidepsin

FIG. 73




FIG. 74A




FIG. 74B




FIG. 75A




FIG. 75B




FIG. 76A




FIG. 76B




FIG. 77A




FIG. 77B




FIG. 78A




FIG. 78B




FIG. 79A




FIG. 79B



AP1 + Palbociclib, Simultaneously
AP1 pretreat 24 hrs
Palbociclib pretreat 24 hrs
MCF-7 Cells Proliferation (Fraction of Control)
1.2
0.8
0.4
0.0
Control
0.047 µM AP1 + 0.047 µM Palbociclib
0.094 µM AP1 + 0.094 µM Palbociclib
0.1875 µM AP1 + 0.1875 µM Palbociclib
0.375 µM AP1 + 0.375 µM Palbociclib
0.75 µM AP1 + 0.75 µM Palbociclib
1.5 µM AP1 + 1.5 µM Palbociclib
3.0 µM AP1 + 3.0 µM Palbociclib

FIG. 80



AP1 pretreat 24 hrs
AP1
AP1 + 0.3 μM Palbociclib
AP1 + 0.1 μM Palbociclib
AP1 + 0.3 μM Palbociclib
Palbociclib pretreat 24 hrs
AP1
AP1 + 0.3 μM Palbociclib
AP1 + 0.1 μM Palbociclib
AP1 + 0.3 μM Palbociclib
MCF-7 Cell Proliferation (Fraction of control cells)
1.5
1.0
0.5
0.0
-4
-2
0
2
AP1 (log,μM)

FIG. 81



AP1 pretreat 24 hrs
Palbociclib
Palbociclib + 0.1 µM AP1
Palbociclib + 0.3 µM AP1
Palbociclib + 1 µM AP1
Palbociclib pretreat 24 hrs
Palbociclib
Palbociclib + 0.1 µM AP1
Palbociclib + 0.3 µM AP1
Palbociclib + 1 µM AP1
MCF-7 Cell Proliferation (Fraction of control cells)
1.5
1.0
0.5
0.0
-4
-2
0
2
Palbociclib (Log, µM)

FIG. 82



AP1
AP1 + 0.01 µM Dex
AP1 + 0.1 µM Dex
AP1 + 1.0 µM Dex
OD450 nm
1.5
1.0
0.5
0.0
-4
-2
0
2
AP1 (log,µM)

FIG. 83




FIG. 84A




FIG. 84B




FIG. 85A




FIG. 85B




FIG. 86A




FIG. 86B




FIG. 87A




FIG. 87B




FIG. 88A




FIG. 88B




FIG. 89A




FIG. 89B




FIG. 90A

FIG. 90B

FIG. 90C

FIG. 90D

FIG. 90E




FIG. 91B




FIG. 91D




FIG. 91A




FIG. 91C




FIG. 92B

FIG. 92A




FIG. 92C



antagonism
additivity
synergy
Romidepsin
Log(CI)
2
1
0
-1
-2
0
0.5
1
Fa
Failed Range

FIG. 93




FIG. 94A

FIG. 94B

FIG. 94C